| The Wnt/β-catenin pathway in ovarian cancer: a review RC Arend, AI Londoño-Joshi, JM Straughn Jr, DJ Buchsbaum Gynecologic oncology 131 (3), 772-779, 2013 | 492 | 2013 |
| Multi-targeted therapy of cancer by niclosamide: A new application for an old drug Y Li, PK Li, MJ Roberts, RC Arend, RS Samant, DJ Buchsbaum Cancer letters 349 (1), 8-14, 2014 | 368 | 2014 |
| Inhibition of Wnt/β-catenin pathway by niclosamide: A therapeutic target for ovarian cancer RC Arend, AI Londoño-Joshi, RS Samant, Y Li, M Conner, B Hidalgo, ... Gynecologic oncology 134 (1), 112-120, 2014 | 183 | 2014 |
| Endometrial cancer: Molecular markers and management of advanced stage disease RC Arend, BA Jones, A Martinez, P Goodfellow Gynecologic oncology 150 (3), 569-580, 2018 | 162 | 2018 |
| The tumor-associated glycosyltransferase ST6Gal-I regulates stem cell transcription factors and confers a cancer stem cell phenotype MJ Schultz, AT Holdbrooks, A Chakraborty, WE Grizzle, CN Landen, ... Cancer research 76 (13), 3978-3988, 2016 | 161 | 2016 |
| A ketogenic diet reduces central obesity and serum insulin in women with ovarian or endometrial cancer CW Cohen, KR Fontaine, RC Arend, RD Alvarez, CA Leath III, WK Huh, ... The Journal of nutrition 148 (8), 1253-1260, 2018 | 150 | 2018 |
| Favorable effects of a ketogenic diet on physical function, perceived energy, and food cravings in women with ovarian or endometrial cancer: a randomized, controlled trial CW Cohen, KR Fontaine, RC Arend, T Soleymani, BA Gower Nutrients 10 (9), 1187, 2018 | 133 | 2018 |
| Long-term outcome and natural history of uterine adenosarcomas R Arend, M Bagaria, SN Lewin, X Sun, I Deutsch, WM Burke, TJ Herzog, ... Gynecologic oncology 119 (2), 305-308, 2010 | 132 | 2010 |
| Uterine neoplasms, version 1.2023, NCCN clinical practice guidelines in oncology N Abu-Rustum, C Yashar, R Arend, E Barber, K Bradley, R Brooks, ... Journal of the National Comprehensive Cancer Network 21 (2), 181-209, 2023 | 113 | 2023 |
| Failure to rescue as a source of variation in hospital mortality for ovarian cancer JD Wright, TJ Herzog, Z Siddiq, R Arend, AI Neugut, WM Burke, SN Lewin, ... Journal of clinical oncology 30 (32), 3976-3982, 2012 | 101 | 2012 |
| Histone methyltransferase EZH2: a therapeutic target for ovarian cancer BA Jones, S Varambally, RC Arend Molecular cancer therapeutics 17 (3), 591-602, 2018 | 93 | 2018 |
| Effect of niclosamide on basal-like breast cancers AI Londoño-Joshi, RC Arend, L Aristizabal, W Lu, RS Samant, BJ Metge, ... Molecular cancer therapeutics 13 (4), 800-811, 2014 | 90 | 2014 |
| Uterine carcinosarcoma R Arend, JA Doneza, JD Wright Current opinion in oncology 23 (5), 531-536, 2011 | 87 | 2011 |
| Endometrial cancer: A society of gynecologic oncology evidence-based review and recommendations CA Hamilton, B Pothuri, RC Arend, FJ Backes, PA Gehrig, PT Soliman, ... Gynecologic oncology 160 (3), 817-826, 2021 | 86* | 2021 |
| Homologous recombination deficiency: concepts, definitions, and assays MD Stewart, D Merino Vega, RC Arend, JF Baden, O Barbash, ... The oncologist 27 (3), 167-174, 2022 | 85 | 2022 |
| Implementation and utilization of the molecular tumor board to guide precision medicine S Harada, R Arend, Q Dai, JA Levesque, TS Winokur, R Guo, MJ Heslin, ... Oncotarget 8 (34), 57845, 2017 | 80 | 2017 |
| Targeting the Wnt/β-catenin pathway in primary ovarian cancer with the porcupine inhibitor WNT974 JD Boone, RC Arend, BE Johnston, SJ Cooper, SA Gilchrist, ... Laboratory Investigation 96 (2), 249-259, 2016 | 77 | 2016 |
| Ovarian cancer stem cells: Can targeted therapy lead to improved progression-free survival? CLW Haygood, RC Arend, JM Straughn, DJ Buchsbaum World journal of stem cells 6 (4), 441, 2014 | 75 | 2014 |
| Folate and folate receptor alpha antagonists mechanism of action in ovarian cancer CL Walters, RC Arend, DK Armstrong, RW Naumann, RD Alvarez Gynecologic oncology 131 (2), 493-498, 2013 | 75 | 2013 |
| Niclosamide and its analogs are potent inhibitors of Wnt/β-catenin, mTOR and STAT3 signaling in ovarian cancer RC Arend, AI Londoño-Joshi, A Gangrade, AA Katre, C Kurpad, Y Li, ... Oncotarget 7 (52), 86803, 2016 | 72 | 2016 |
